Elfabrio
Payments companies reported to CMS as associated with Elfabrio. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Elfabrio, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Elfabrio
These are the largest totals companies reported as associated with Elfabrio. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| David Warnock | Birmingham, AL | Nephrology (Internal Medicine) | $35,806.63 |
| Ozlem Goker-Alpan | Fairfax, VA | Pediatrics | $29,794.74 |
| Brian Shayota | Salt Lake City, UT | Pediatrics | $27,805.93 |
| Brian Jones | Rochester, MN | Internal Medicine | $26,877.77 |
| Eric Wallace | Birmingham, AL | Nephrology (Internal Medicine) | $19,674.12 |
| John Bernat | Iowa City, IA | Clinical Genetics (M.D.) | $15,154.99 |
| Donna Griebel | Lawrence, KS | Internal Medicine | $13,650.00 |
| Robert Hopkin | Cincinnati, OH | Clinical Genetics (M.D.) | $12,781.66 |
| Raphael Schiffmann | Dallas, TX | Neurology With Special Qualifications In Child Neurology | $11,535.57 |
| Myrl Holida | Iowa City, IA | Physician Assistant | $11,504.36 |
Prescribed Elfabrio?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.